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1. INTRODUCTION {#dom13991-sec-0001}
===============

Uric acid acts as an antioxidant, particularly in the extracellular environment.[1](#dom13991-bib-0001){ref-type="ref"} It has been estimated that uric acid comprises approximately half of the total antioxidant capacity of biological fluids in humans. However, in cytoplasm or the acidic/hydrophobic milieu of atherosclerotic plaques, uric acid is converted to a pro‐oxidant agent that promotes oxidative stress, which may accelerate cardiovascular (CV) disease.[2](#dom13991-bib-0002){ref-type="ref"} Several epidemiological studies have suggested a positive relationship between elevated serum uric acid levels and risk of CV events (including coronary heart disease \[CHD\], stroke, and heart failure \[HF\]), metabolic syndrome, diabetes, and chronic kidney disease.[2](#dom13991-bib-0002){ref-type="ref"}, [3](#dom13991-bib-0003){ref-type="ref"} Yet, it remains unclear as to whether uric acid offers prognostic information in patients with established CV disease. Finally, to date, no study has evaluated whether baseline levels of uric acid modulate the efficacy of anti‐hyperglycaemic therapy. As treatment with sodium‐glucose co‐transporter‐2 inhibitors has been shown to lower uric acid levels, clinical trials evaluating this class of glucose‐lowering agents may be of particular interest to explore the interplay between serum uric acid levels and clinical outcomes.[4](#dom13991-bib-0004){ref-type="ref"} In an effort to address these questions, we evaluated the independent relationship between uric acid and CV outcomes in the EMPA‐REG OUTCOME trial.

2. METHODS {#dom13991-sec-0002}
==========

EMPA‐REG OUTCOME (NCT01131676, [ClinicalTrials.gov](http://clinicaltrials.gov)) enrolled patients with type 2 diabetes, established CV disease, and an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m^2^ at baseline. A total of 7020 patients were treated with empagliflozin 10 mg/d, empagliflozin 25 mg/d or placebo, in addition to standard of care.[5](#dom13991-bib-0005){ref-type="ref"} Background glucose‐lowering therapy was unchanged for the first 12 weeks and could then be adjusted to achieve glycaemic control. Throughout the study, investigators were encouraged to treat CV risk factors to achieve optimal standard of care. *Post hoc*, we categorized pre‐randomization baseline uric acid levels into tertiles (\<309.30 μmol/L; 309.30 to \<387.21 μmol/L; ≥387.21 μmol/L), and assessed differences in outcomes between tertiles. We first analysed the relationship with baseline uric acid as a continuous (vs. categorical) variable in a multivariable Cox regression model. We then explored the associations between uric acid and outcomes in the placebo and empagliflozin groups separately, using an extended multivariable Cox regression model that included the primary model adjustment of age, sex, baseline body mass index (BMI; categorical), baseline glycated haemoglobin (HbA1c) level (categorical), baseline eGFR (categorical) and region, as well as baseline use of diuretics, baseline anti‐gout medication, baseline HF, and tertile of baseline uric acid. Outcomes assessed were CV death, hospitalization for heart failure (HHF), the composite of HHF/CV death, all‐cause mortality (ACM), three‐point major adverse CV events (MACE), and incident or worsening nephropathy. We then explored the treatment effects of empagliflozin versus placebo by tertile of baseline uric acid, using Cox regression analysis for time to first event in patients treated with ≥1 dose of study drug; this model included the variables age, sex, baseline BMI (categorical), baseline HbA1c (categorical), baseline eGFR (categorical), region, treatment, tertile of baseline uric acid and interaction of treatment\*tertile of baseline uric acid. The occurrence of gout (as defined by the preferred terms "gout", "gouty arthritis", "gouty tophus") during treatment or within 7 days after the last dose of study drug was reported descriptively. Analyses were conducted using SAS® Version 9.4.

3. RESULTS {#dom13991-sec-0003}
==========

The median (interquartile range) baseline plasma uric acid level was 344.98 μmol/L (286.10--409.82) μmol/L (n = 7017). Empagliflozin reduced plasma uric acid levels compared to placebo during follow‐up in the overall study population, as shown previously.[5](#dom13991-bib-0005){ref-type="ref"} Baseline characteristics were generally balanced across tertiles, with a few exceptions: compared with the lowest tertile of uric acid, the highest tertile of uric acid contained more men (77.8% vs. 63.5%), had a lower mean eGFR (64.6 ± 19.3 vs. 83.1 ± 21.0 mL/min/1.73 m^2^), more prevalent history of HF (14.4% vs. 8.1%), and greater use of diuretics (58.9% vs. 30.6%) and anti‐gout medication (8.0% vs. 4.2%; [Table S1](#dom13991-supitem-0001){ref-type="supplementary-material"}). However, there was no difference in anti‐gout medication use between the empagliflozin and placebo groups at baseline. Moreover, the number of patients in the trial with gout was low, with no differences reported in the placebo versus empagliflozin treatment groups (1.5% vs. 1.1% in patients without known gout at baseline, and 12.4% vs 13.9% in those with known gout at baseline, in the placebo vs. empagliflozin groups, respectively).

Analysis of the relationship with baseline uric acid as a continuous (vs. categorical) variable in a multivariable Cox regression model confirmed that higher baseline uric acid was associated with higher risk for all outcomes in the placebo and empagliflozin groups (Table [1](#dom13991-tbl-0001){ref-type="table"}).

###### 

Multivariable Cox regression of baseline uric acid as a continuous variable to outcome in the placebo and empagliflozin groups

                                      Placebo   Empagliflozin                                            
  ----------------------------------- --------- ------------------- ---------- ----- ------------------- ----------
  Three‐point MACE                    282       1.06 (0.98--1.15)   0.1406     490   1.15 (1.09--1.22)   \<0.0001
  CV death                            137       1.09 (0.98--1.22)   0.1039     172   1.18 (1.08--1.30)   0.0005
  HHF                                 94        1.25 (1.10--1.41)   0.0006     126   1.21 (1.10--1.34)   0.0002
  HHF or CV death                     197       1.14 (1.04--1.24)   0.0053     265   1.19 (1.11--1.28)   \<0.0001
  ACM                                 194       1.07 (0.98--1.17)   0.1528     269   1.18 (1.09--1.27)   \<0.0001
  Incident or worsening nephropathy   387       1.17 (1.09--1.25)   \<0.0001   525   1.14 (1.08--1.21)   \<0.0001

Abbreviations: ACM, all‐cause mortality; BMI, body mass index; CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events.

Cox model included age, sex, baseline BMI (categorical), baseline HbA1c (categorical), baseline eGFR (categorical), region, baseline uric acid (continuous), use of baseline diuretics, baseline anti‐gout medication and baseline HF. The composite endpoint of HHF or CV death excludes fatal stroke.

Overall, in both treatment groups, the risk of adverse outcomes was increased within the highest tertile of uric acid at baseline versus the lowest tertile, although with hazard ratios (HRs) all \>1, for three‐point MACE and ACM, the relationships were less clear: in the placebo group the estimated HRs of the third versus first tertile were greater than, but close to, 1 (Figure [1](#dom13991-fig-0001){ref-type="fig"}).

![Multivariable Cox regression between tertiles of uric acid at baseline (\<309.30 μmol/L, 309.30 to \<387.21 μmol/L, and ≥387.21 μmol/L) for cardiovascular (CV) and kidney outcomes in the placebo and empagliflozin treatment groups. \*Cox regression analysis was used to derive the hazard ratio (HR) and 95% confidence interval (CI). Cox regression model included age, sex, baseline body mass index (BMI; categorical), baseline glycated haemoglobin (HbA1c; categorical), baseline estimated glomerular filtration rate (eGFR; categorical), region, baseline use of diuretics, baseline anti‐gout medication, baseline heart failure (HF), and tertiles of baseline uric acid. ^†^Excludes fatal stroke. 3P‐MACE, three‐point major adverse CV events; ACM, all‐cause mortality; HHF, hospitalization for heart failure](DOM-22-1207-g001){#dom13991-fig-0001}

Empagliflozin improved all cardio‐renal outcomes across tertiles of baseline uric acid (Figure [2](#dom13991-fig-0002){ref-type="fig"}); the *P* values for trend for tertile of uric acid, for both placebo and empagliflozin, are shown in [Table S2](#dom13991-supitem-0001){ref-type="supplementary-material"}.

![Effect of empagliflozin versus placebo on major outcomes by tertile of baseline uric acid. Cox regression analysis for time to first event in patients treated with ≥1 dose of study drug. Cox regression model included age, sex, baseline body mass index (BMI; categorical), baseline glycated haemoglobin (HbA1c; categorical), baseline estimated glomerular filtration rate (eGFR; categorical), region, treatment, tertile of baseline uric acid (UA) and interaction of treatment\*tertile of baseline uric acid. *P* values for trend for tertiles of uric acid, for both placebo and empagliflozin, are shown in [Table S2](#dom13991-supitem-0001){ref-type="supplementary-material"}. ^†^Excludes fatal stroke. 3P‐MACE, three‐point major adverse CV events; ACM, all‐cause mortality; CI, confidence interval; CV, cardiovascular; HHF, hospitalization for heart failure](DOM-22-1207-g002){#dom13991-fig-0002}

4. DISCUSSION {#dom13991-sec-0004}
=============

This *post hoc* analysis of EMPA‐REG OUTCOME in patients with type 2 diabetes and established CV disease demonstrates that baseline uric acid levels are independently associated with adverse cardio‐renal outcomes. Furthermore, empagliflozin consistently reduced cardio‐renal outcomes irrespective of baseline uric acid.

Data from *in vitro* and animal studies indicate that elevated levels of serum uric acid are associated with an increased risk of CV and kidney disease.[3](#dom13991-bib-0003){ref-type="ref"} These findings are supported by evidence from a number of epidemiological studies; however, differences in the methodology, coupled with the effect of changes in kidney function on serum uric acid concentrations, make it difficult to draw firm conclusions.[3](#dom13991-bib-0003){ref-type="ref"} This is also the case with Mendelian randomization studies and pilot clinical trials of uric acid‐lowering therapies, where results are mixed, and interpretation is often complicated by factors such as non‐homogenous populations and study design issues.[3](#dom13991-bib-0003){ref-type="ref"} The conclusions of a Scientific Workshop of the National Kidney Foundation in 2016 were that the role of serum uric acid in CV and kidney disease remains to be determined and requires further investigation in large‐scale trials.[3](#dom13991-bib-0003){ref-type="ref"}

Recent meta‐analyses have continued to explore the relationship between uric acid and risk of cardio‐renal disease. Braga et al[6](#dom13991-bib-0006){ref-type="ref"} reported an association between hyperuricaemia and CHD incidence (risk ratio \[RR\] 1.206, confidence interval \[CI\] 1.066--1.364; *P* = 0.003) and CHD mortality (RR 1.209, CI 1.003--1.457; *P* = 0.047), with the risk of CHD events greater in women than in men. Huang et al[7](#dom13991-bib-0007){ref-type="ref"} showed that elevated levels of serum uric acid independently predict the risk of ACM and the combined endpoint of readmission for, or death from, acute HF. Patients with the highest serum uric acid levels had an increased risk of ACM (RR 1.43, 95% CI 1.31--1.56) and the combined endpoint (RR 1.68, 95% CI 1.33--2.13).[7](#dom13991-bib-0007){ref-type="ref"}

A meta‐analysis of 12 randomized controlled trials, evaluating the efficacy of uric acid‐lowering therapy on progression of chronic kidney disease, demonstrated that the risk of worsening kidney function or end‐stage renal disease or death was significantly lowered in the treatment group versus the control group (relative risk 0.39, 95% CI 0.28--0.52; *P* \< 0.01).[8](#dom13991-bib-0008){ref-type="ref"}

Shao et al[9](#dom13991-bib-0009){ref-type="ref"} conducted a meta‐analysis of 12 studies in patients with type 2 diabetes to examine the effect of serum uric acid on progression of ACM (six studies), stroke (two studies) and CHD (four studies). The risk of ACM and stroke increased with each corresponding rise in serum uric acid level of 59 μmol/L (HR 1.06, 95% CI, 1.03--1.09 and HR 1.19, 95% CI, 1.08--1.31, respectively); for CHD, there was a trend towards a higher risk of CHD with a 59‐μmol/L increase in serum uric acid, although this did not reach statistical significance.[9](#dom13991-bib-0009){ref-type="ref"}

The results of these recent meta‐analyses lend further weight to the association between serum uric acid levels and risk of CV and kidney disease, including in patients with type 2 diabetes. Furthermore, they are supportive of the findings from the present *post hoc* analysis of the EMPA‐REG OUTCOME trial, which also showed that uric acid levels appear to be associated with CV and kidney outcomes in patients with type 2 diabetes and CV disease. Overall, in both treatment groups the risk of outcomes was increased within the highest versus lowest tertile of baseline uric acid, with all HRs \>1, although the association was less clear for three‐point MACE and ACM in the placebo group. In these comparisons, not all 95% CIs for the HRs excluded 1, which may be attributable to the low sample size and event numbers within the subgroups and treatment arms: the study was not powered to show any associations in subgroups. For this reason, we also examined uric acid as a continuous variable and again demonstrated an association of uric acid with outcomes in both treatment groups. Empagliflozin consistently reduced these outcomes across the range of baseline uric acid levels, and this observation supports the mediation analysis undertaken in EMPA‐REG OUTCOME, demonstrating that changes in uric acid mediated \~20% to 25% of the reduction in CV death and HHF or HF death seen with empagliflozin.[10](#dom13991-bib-0010){ref-type="ref"}, [11](#dom13991-bib-0011){ref-type="ref"} Cause and effect relationships, however, will need further study.
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